1. Academic Validation
  2. Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer

Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer

  • Neoplasia. 2023 Mar 3;38:100890. doi: 10.1016/j.neo.2023.100890.
Abdol-Hossein Rezaeian 1 Liem Minh Phan 2 Xiaobo Zhou 3 Wenyi Wei 4 Hiroyuki Inuzuka 5
Affiliations

Affiliations

  • 1 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States of America.
  • 2 David Grant USAF Medical Center, Clinical Investigation Facility, 60th Medical Group, Travis Air Force Base, CA 94535, United States of America.
  • 3 Brigham and Women's Hospital, Channing Division of Network Medicine, Boston, MA, United States of America.
  • 4 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States of America. Electronic address: wwei2@bidmc.harvard.edu.
  • 5 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States of America; Brigham and Women's Hospital, Channing Division of Network Medicine, Boston, MA, United States of America.
Abstract

SKP2, an F-box protein of the SCF type of the E3 ubiquitin ligase complex, plays an important function in driving tumorigenesis through the destruction of numerous tumor-suppressive proteins. Besides its critical role in cell cycle regulation, proto-oncogenic functions of SKP2 have also been shown in a cell cycle regulation-independent manner. Therefore, uncovering novel physiological upstream regulators of SKP2 signaling pathways would be essential to retard aggressive malignancies. Here, we report that elevation of SKP2 and EP300 transcriptomic expression is a hallmark of castration-resistant prostate Cancer. We also found that SKP2 acetylation is likely a critical driven event in castration-resistant prostate Cancer cells. Mechanistically, SKP2-acetylation is mediated by the p300 acetyltransferase Enzyme for post-translational modification (PTM) event that is induced upon stimulation with dihydrotestosterone (DHT) in prostate Cancer cells. Moreover, ectopic expression of acetylation-mimetic K68/71Q mutant of SKP2 in LNCaP cells could confer resistance to androgen withdrawal-induced growth arrest and promotes prostate Cancer stem cell (CSC)-like traits including survival, proliferation, stemness formation, lactate production, migration, and invasion. Furthermore, inhibition of p300-mediated SKP2 acetylation or SKP2-mediated p27-degradation by pharmacological inhibition of p300 or SKP2 could attenuate epithelial-mesenchymal transition (EMT) and the proto-oncogenic activities of the SKP2/p300 and Androgen Receptor (AR) signaling pathways. Therefore, our study identifies the SKP2/p300 axis as a possible molecular mechanism driving castration-resistant prostate cancers, which provides pharmaceutical insight into inactivation of the SKP2/p300 axis for restriction of CSC-like properties, thereby benefiting clinical diagnosis and Cancer therapy.

Keywords

Castration-resistant; Pharmacological inhibition; Prostate cancer; SKP2; p300.

Figures
Products